CDK4 and breast cancer: There are currently multiple on-going clinical trials assessing the combination of checkpoint blockade with PARP inhibitors (NCT03594396, NCT02849496) and CDK4/6 inhibitors (NCT02778685, NCT02779751, NCT0314728, NCT03147287, NCT03573648, NCT03294694) in HR+ breast cancer.